Klaus Felix1, Oliver Hauck, Martina Schnölzer, Tore Kempf, Uwe Warnken, Kathrin Schneider, Frank Bergmann, Stefan Fritz, Jens Werner. 1. From the *Department of General Surgery, University of Heidelberg, Heidelberg; †Department of Plant Biochemistry, Dahlem Centre of Plant Sciences, Freie Universität Berlin, Berlin; ‡Functional Proteome Analysis, German Cancer Research Center (DKFZ); and §Institute of Pathology, University of Heidelberg, Heidelberg and ∥Department of General-, Visceral-, Transplantations-, Vascular- and Thorax-Surgery, Ludwig Maximilian University of Munich, Munich, Germany.
Abstract
OBJECTIVES: The lack of specific biochemical markers is a major drawback for the diagnosis of autoimmune pancreatitis (AIP). The aims were to characterize the autoantibody profiles in AIP and pancreatic ductal adenocarcinoma (PDAC) and to identify circulating autoantibodies that could be diagnostic markers differentiating PDAC and the AIP subtypes. METHODS: Tissue lysates obtained from the resected pancreas of patients with AIP and patients with PDAC were separated by 2-dimensional polyacrylamide gel electrophoresis subsequently immunoblotted with autologous sera. The immunoreactive spots were subjected to nanoscale liquid chromatography-electrospray ionization tandem mass spectrometry to identify serum autoantibodies to tissue-derived autoantigens associated with AIP and PDAC. Autoantibody concentrations for selected autoantigens were assessed by enzyme-linked immunosorbent assays. RESULTS: A total of 115 immunoreactive spots were identified by 2-dimensional polyacrylamide gel electrophoresis/immunobloting. Nanoscale liquid chromatography-electrospray ionization tandem mass spectrometry-based analysis revealed 68 autoantigens in AIP, 26 in PDAC, and 21 present in both diseases. Assessment of 13 selected AIP autoantibody serum levels revealed that 7 of them had significantly higher titers in AIP versus PDAC. IgG-directed against transaldolase could significantly differentiate between the 2 AIP subtypes. CONCLUSIONS: The novel panel of AIP autoantibodies is promising to supplement the predictive tests for AIP of the currently known autoantigens and represent a basis for a combined blood test to differentiate AIP from PDAC in the future.
OBJECTIVES: The lack of specific biochemical markers is a major drawback for the diagnosis of autoimmune pancreatitis (AIP). The aims were to characterize the autoantibody profiles in AIP and pancreatic ductal adenocarcinoma (PDAC) and to identify circulating autoantibodies that could be diagnostic markers differentiating PDAC and the AIP subtypes. METHODS: Tissue lysates obtained from the resected pancreas of patients with AIP and patients with PDAC were separated by 2-dimensional polyacrylamide gel electrophoresis subsequently immunoblotted with autologous sera. The immunoreactive spots were subjected to nanoscale liquid chromatography-electrospray ionization tandem mass spectrometry to identify serum autoantibodies to tissue-derived autoantigens associated with AIP and PDAC. Autoantibody concentrations for selected autoantigens were assessed by enzyme-linked immunosorbent assays. RESULTS: A total of 115 immunoreactive spots were identified by 2-dimensional polyacrylamide gel electrophoresis/immunobloting. Nanoscale liquid chromatography-electrospray ionization tandem mass spectrometry-based analysis revealed 68 autoantigens in AIP, 26 in PDAC, and 21 present in both diseases. Assessment of 13 selected AIP autoantibody serum levels revealed that 7 of them had significantly higher titers in AIP versus PDAC. IgG-directed against transaldolase could significantly differentiate between the 2 AIP subtypes. CONCLUSIONS: The novel panel of AIP autoantibodies is promising to supplement the predictive tests for AIP of the currently known autoantigens and represent a basis for a combined blood test to differentiate AIP from PDAC in the future.
Authors: Niall Brindl; Henning Boekhoff; Andrea S Bauer; Matthias M Gaida; Hien T Dang; Jörg Kaiser; Jörg D Hoheisel; Klaus Felix Journal: Cancers (Basel) Date: 2022-07-22 Impact factor: 6.575
Authors: Sahar Ghassem-Zadeh; Matthias M Gaida; Szilard Szanyi; Hans Acha-Orbea; Jean-Louis Frossard; Ulf Hinz; Thilo Hackert; Oliver Strobel; Klaus Felix Journal: J Transl Med Date: 2017-06-02 Impact factor: 5.531
Authors: Sahar Ghassem-Zadeh; Katrin Hufnagel; Andrea Bauer; Jean-Louis Frossard; Masaru Yoshida; Hiromu Kutsumi; Hans Acha-Orbea; Matthias Neulinger-Muñoz; Johannes Vey; Christoph Eckert; Oliver Strobel; Jörg D Hoheisel; Klaus Felix Journal: Int J Mol Sci Date: 2020-03-31 Impact factor: 5.923